Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Medicine Research Profiles
Home
Profiles
Departments, Divisions and Centers
Research output
Pathological features of fatty liver disease
Matthew M. Yeh
, Elizabeth M. Brunt
Division of Anatomic and Molecular Pathology (AMP)
Institute of Clinical and Translational Sciences (ICTS)
Research output
:
Contribution to journal
›
Review article
›
peer-review
304
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Pathological features of fatty liver disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pathological Features
100%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Fatty Liver Disease
100%
Alcoholic Liver Disease
80%
Steatosis
40%
Chronic Liver Disease
40%
Hepatocellular Carcinoma
20%
Clinical Trials
20%
Patient Outcomes
20%
Liver Disease
20%
Biopsy Specimen
20%
Pediatric
20%
Nonalcoholic Steatohepatitis
20%
Pathological Lesions
20%
Cirrhosis
20%
Steatohepatitis
20%
Obesity Prevalence
20%
Pathologist
20%
Prognostic Factors
20%
End-stage Liver Disease
20%
Increasing Prevalence
20%
Diabetes Prevalence
20%
Pathological Analysis
20%
Benign Liver Tumors
20%
Histological Scoring System
20%
Malignant Liver Tumor
20%
Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Fatty Liver
100%
Alcohol Liver Disease
66%
Steatosis
33%
Chronic Liver Disease
33%
Disease
33%
Hepatocellular Carcinoma
16%
Prevalence
16%
Clinical Trial
16%
Liver Disease
16%
Diabetes
16%
Pediatrics
16%
Steatohepatitis
16%
Liver Cirrhosis
16%
Pathologist
16%
Scoring System
16%
Prognostic Factor
16%
Liver Tumor
16%
End Stage Liver Disease
16%
Biopsy Technique
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Fatty Liver
100%
Alcohol Liver Disease
66%
Steatosis
33%
Chronic Liver Disease
33%
Liver Cell Carcinoma
16%
Clinical Trial
16%
Liver Disease
16%
Liver Cirrhosis
16%
Prevalence
16%
End Stage Liver Disease
16%
Liver Tumor
16%